← Back to Calendar

Vera Therapeutics Q1 2026 Earnings

Vera Therapeutics · $VERA
Standard Review Earnings
Catalyst Date
May 8, 2026
Time Remaining
38 days
Review Type
Standard (10 mo)

Live Company Data NGM

Updated 18m ago · Data: FMP
Current Price
$38.10 +43.07%
+$11.47 today
Day: $37.90 – $39.05
Market Cap
N/A
52-Week Range
$18.53
$56.05
Current price is at 52% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.

Indication

Q1 2026 earnings + atacicept PDUFA July 7 commercial preparation update

Key Notes

Q1 2026 earnings expected ~May 8, 2026. Key updates: comercial launch preparations for atacicept (PDUFA July 7, 2026 for IgAN); cash runway guidance; manufacturing and supply chain readiness. Would be first commercial product for Vera. ORIGIN Phase 3 showed 46% proteinuria reduction vs placebo.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar